Back to Search
Start Over
Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
- Source :
-
Obstetrics & Gynecology . Nov2018, Vol. 132 Issue 5, p1091-1100. 10p. - Publication Year :
- 2018
-
Abstract
- <bold>Objective: </bold>To estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer.<bold>Methods: </bold>Eligibility included all asymptomatic women 50 years of age or older and women 25 years of age or older with a documented family history of ovarian cancer. From 1987 to 2017, 46,101 women received annual ultrasound screening in a prospective cohort trial. Women with a persisting abnormal screen underwent tumor morphology indexing, serum biomarker analysis, and surgery.<bold>Results: </bold>Seventy-one invasive epithelial ovarian cancers and 17 epithelial ovarian tumors of low malignant potential were detected. No women with a low malignant potential tumor experienced recurrent disease. Stage distribution for screen-detected invasive epithelial ovarian cancers was stage I-30 (42%), stage II-15 (21%), stage III-26 (37%), and stage IV-0 (0%). Follow-up varied from 9.2 months to 27 years (mean 7.9 years). Disease-specific survival at 5, 10, and 20 years for women with invasive epithelial ovarian cancer detected by screening was 86±4%, 68±7%, and 65±7%, respectively, vs 45±2%, 31±2%, and 19±3%, respectively, for unscreened women with clinically detected ovarian cancer from the same geographic area who were treated at the same institution by the same treatment protocols (P<.001). Twenty-seven percent of screen-detected malignancies were type I and 73% were type II. The disease-specific survival of women with type I and type II screen-detected tumors was significantly higher than that of women with clinically detected type I and type II tumors and was related directly to earlier stage at detection.<bold>Conclusion: </bold>Annual ultrasound screening of at-risk asymptomatic women was associated with lower stage at detection and increased 5-, 10-, and 20-year disease-specific survival of women with both type I and type II epithelial ovarian cancer.<bold>Clinical Trial Registration: </bold>OnCore Clinical Trials Management System, NCI-2013-01954. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00297844
- Volume :
- 132
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Obstetrics & Gynecology
- Publication Type :
- Academic Journal
- Accession number :
- 133583236
- Full Text :
- https://doi.org/10.1097/AOG.0000000000002921